Table 2 Therapeutic regimen and characteristic of included participants
From: Conbercept for patients with age-related macular degeneration: a systematic review
Study ID | Therapeutic regimen of intervention group | Therapeutic regimen of comparison group | Gender(male/female): intervention group vs comparison group | Age(years): intervention group vs comparison group | Course of disease: intervention group vs comparison group |
|---|---|---|---|---|---|
Li YY, 2017 [17] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 16/11 vs 14/13 | 76.8 ± 12.6(58–85) vs 77.6 ± 11.9(59–83) | NA |
Mei HY, 2017 [18] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 17/16 vs 16/17 | 69.4 ± 4.3(63–72) vs 69.5 ± 4.1(63–71) | 3.1 ± 0.5y(2-4y) vs 3.2 ± 0.6y(2-5y) |
Song W, 2016 [19] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 30/26 vs 29/27 | 62.36 ± 6.56(53–81) vs 63.29 ± 6.45(54–82) | NA |
Liu ZN, 2016 [20] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 11/9 vs 12/8 | 65.41 ± 6.37(57–86) vs 65.36 ± 6.74(56–85) | 3.81 ± 1.10y(6 m-10y) vs 3.88 ± 1.20y(7 m-11y) |
Zhang HX, 2016 [21] | Conbercept, NA | Ranibizumab, NA | 12/13 vs 13/12 | 68.79 ± 7.21(54–81) vs 69.03 ± 7.01(53–82) | 6.13 ± 4.27 m(7d-14 m) vs 6.25 ± 4.45 m(3d-15 m) |
Liu R, 2015 [22] | Conbercept, 1.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | NA | 65.5 ± 8.1(53–83) vs 65.2 ± 8.3(54–81) | 18.8 ± 4.1 m(8-31 m) vs 19.0 ± 4.2 m (9-32 m) |
Wang NF, 2017 [23] | Conbercept, 0.5 mg, intravitreal injection | Ranibizumab, 0.5 mg, intravitreal injection | 19/19 vs 20/18 | 62.89 ± 5.46(51–75) vs 62.85 ± 5.41(52–74) | NA |
Lyu P, 2016 [24] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 22/20 vs 21/21 | 62.7 ± 5.3(51–73) vs 62.1 ± 4.9(49–70) | NA |
Zheng MW, 2017 [25] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 25/17 vs 26/17 | 65.34 ± 2.29(61–72) vs 65.13 ± 2.27(61–74) | NA |
Wang XX, 2015 [26] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | 17/13 vs 16/14 | 70.4 ± 8.4 vs 69.7 ± 8.1 | NA |
Qin MM, 2016 [27] | Conbercept, 1.0 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | 20/21 vs 22/19 | 65.8 ± 7.5(54–81) vs 64.9 ± 7.7(51–79) | 5.7 ± 4.4y(9 m-25y) vs 4.7 ± 3.2y(11 m-21y) |
Li L, 2017 [28] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | NA | 62.28 ± 3.21(52–82) vs 63.12 ± 4.36(53–83) | NA |
Zhang X, 2015 [29] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | NA | 64.19 ± 4.31(54–85) vs 65.43 ± 5.76(55–86) | NA |
Zhu Y, 2017 [30] | Conbercept, NA | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | NA | NA | NA |
He XT, 2015 [31] | Conbercept, 1.0 mg, intravitreal injection. | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 14/16 vs 13/17 | 61.52 ± 6.8(57–72) vs 61.30 ± 6.2(55–70) | NA |
Han X, 2017 [32] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Triamcinolone acetonide, 0.1 ml, intravitreal injection, once a month, continuous treatment for 3 months. | 16/19 vs 14/21 | 67.54 ± 4.45(55–83) vs 68.12 ± 4.66(54–87) | 3.75 ± 0.64y(0.5-10y) vs 3.94 ± 0.71y(0.5-12y) |
Pan XL, 2017 [33] | Conbercept, 1.0 mg, intravitreal injection | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 20/18 vs 22/16 | 71.62 ± 5.27(63–85) vs 71.59 ± 5.11(62–83) | 15.83 m ± 5.25 m(5-25 m) vs 15.65 m ± 5.34 m(7-29 m) |
Yue JL, 2017 [34] | Conbercept, 0.5 mg, intravitreal injection | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 21/17 vs 22/16 | 69.78 ± 7.52(61–82) vs 69.27 ± 8.36(60–81) | 45.62 ± 14.79 m(5-126 m) vs 46.15 ± 14.34 m(7-123 m) |